As Imaging Takes Center Stage, TTP Labtech Seeks to Carve Own Niche in Drug Screening | GenomeWeb

SAN FRANCISCO — Although cellular imaging was the topic du jour at Cambridge Healthtech Institute’s High-Content Analysis conference here last week, not everyone was necessarily on the same page.

Executives from Royston, UK-based TTP Labtech were in attendance, and although the company didn’t exhibit at the conference, it did present a pair of posters describing the capabilities of its Acumen Explorer microplate scanning cytometer — a non-image-based platform for which the company is still trying to carve an appropriate niche in drug screening.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.